Overview

A Study of Guselkumab in Participants With Systemic Sclerosis

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.
Treatments:
Antibodies, Monoclonal